TY - JOUR
T1 - The effects of digital cognitive behavioural therapy for insomnia on cognitive function
T2 - A randomised, controlled trial
AU - Kyle, Simon D
AU - Hurry, Madeleine E D
AU - Emsley, Richard
AU - Marsden, Antonia
AU - Omlin, Ximena
AU - Juss, Amender
AU - Spiegelhalder, Kai
AU - Bisdounis, Lampros
AU - Luik, Annemarie I
AU - Espie, Colin A
AU - Sexton, Claire E
N1 - © Sleep Research Society 2020. Published by Oxford University Press on behalf of the Sleep Research Society. All rights reserved. For permissions, please e-mail [email protected].
PY - 2020
Y1 - 2020
N2 - STUDY OBJECTIVES: We sought to examine the impact of digital cognitive behavioural therapy (dCBT) for insomnia on both self-reported cognitive impairment and objective cognitive performance.METHODS: The DISCO trial was an online, two-arm, single-blind, randomised clinical trial of dCBT versus wait-list control. Participants were aged 25 years and older, met DSM-5 diagnostic criteria for insomnia disorder and reported difficulties with concentration or memory. Assessments were carried out online at baseline, and 10 and 24 weeks post-randomisation. The primary outcome measure was self-reported cognitive impairment, assessed with the British Columbia Cognitive Complaints Inventory (BC-CCI). Secondary outcomes included tests of cognitive performance, insomnia symptoms, cognitive failures, fatigue, sleepiness, depression and anxiety.RESULTS: 410 participants with insomnia were recruited and assigned to dCBT (N = 205) or wait-list control (N = 205). At 10 weeks post-randomisation the estimated adjusted mean difference for the BC-CCI was -3.03 [95% CI: -3.60,-2.47; p<.0001, d = -0.86], indicating that participants in the dCBT group reported less cognitive impairment than the control group. These effects were maintained at 24 weeks (d = -0.96) and were mediated, in part, via reductions in insomnia severity and increased sleep efficiency. Treatment effects in favour of dCBT, at both 10 and 24 weeks, were found for insomnia severity, sleep efficiency, cognitive failures, fatigue, sleepiness, depression, and anxiety. We found no between-group differences on objective tests of cognitive performance.CONCLUSIONS: Our study shows that dCBT robustly decreases self-reported cognitive impairment at post-treatment and these effects are maintained at 6 months.
AB - STUDY OBJECTIVES: We sought to examine the impact of digital cognitive behavioural therapy (dCBT) for insomnia on both self-reported cognitive impairment and objective cognitive performance.METHODS: The DISCO trial was an online, two-arm, single-blind, randomised clinical trial of dCBT versus wait-list control. Participants were aged 25 years and older, met DSM-5 diagnostic criteria for insomnia disorder and reported difficulties with concentration or memory. Assessments were carried out online at baseline, and 10 and 24 weeks post-randomisation. The primary outcome measure was self-reported cognitive impairment, assessed with the British Columbia Cognitive Complaints Inventory (BC-CCI). Secondary outcomes included tests of cognitive performance, insomnia symptoms, cognitive failures, fatigue, sleepiness, depression and anxiety.RESULTS: 410 participants with insomnia were recruited and assigned to dCBT (N = 205) or wait-list control (N = 205). At 10 weeks post-randomisation the estimated adjusted mean difference for the BC-CCI was -3.03 [95% CI: -3.60,-2.47; p<.0001, d = -0.86], indicating that participants in the dCBT group reported less cognitive impairment than the control group. These effects were maintained at 24 weeks (d = -0.96) and were mediated, in part, via reductions in insomnia severity and increased sleep efficiency. Treatment effects in favour of dCBT, at both 10 and 24 weeks, were found for insomnia severity, sleep efficiency, cognitive failures, fatigue, sleepiness, depression, and anxiety. We found no between-group differences on objective tests of cognitive performance.CONCLUSIONS: Our study shows that dCBT robustly decreases self-reported cognitive impairment at post-treatment and these effects are maintained at 6 months.
U2 - 10.1093/sleep/zsaa034
DO - 10.1093/sleep/zsaa034
M3 - Article
C2 - 32128593
SN - 0161-8105
JO - Sleep
JF - Sleep
ER -